AI-enabled design

Decoy Therapeutics is pioneering a new category of antivirals called Designable Multi-Antivirals (D-MAVs), single adaptable medicines engineered to target mechanisms many viruses share so one drug can work across many of them. Built on the IMP3ACT peptide conjugate platform, which pairs AI-enabled design with rapid synthesis, the company targets flu, RSV and coronaviruses and is working to advance two programs toward the clinic within 24 months.

Read more

machine learning-guided candidate designpeptide conjugate platformrapid synthesis and manufacturing